The company's performance throughout the fourth quarter has been in alignment with expectations and remains in accordance with the established financial plan. Operations have been executed in line with projections, and current funding is secured through the fourth quarter of 2024. The delay in publishing the quarterly report is attributed solely to unforeseen administrative circumstances that falls outside the Company's control.

This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-02-2024 17:20 CET.